title: Antipsychotic treatment in breast cancer patients.
abstract: Special consideration is required when prescribing antipsychotic drugs for patients with an existing diagnosis of breast cancer. The package inserts of all approved antipsychotics contain precautions regarding their administration in this patient group. These drugs are well known to elevate serum prolactin levels to varying degrees. Overexpression of the prolactin receptor is seen in more than 95% of human breast cancers. Many genes that are activated by the prolactin receptor are associated with tumorigenesis and cancer cell proliferation. The authors discuss the pathophysiology, clinical implications, and pertinent preclinical data and make specific recommendations regarding the use of antipsychotics in patients with breast cancer.
authors.forename: Tahir
authors.initials: T
authors.lastname: Rahman
authors.forename: Charles V
authors.initials: CV
authors.lastname: Clevenger
authors.forename: Virginia
authors.initials: V
authors.lastname: Kaklamani
authors.forename: John
authors.initials: J
authors.lastname: Lauriello
authors.forename: Austin
authors.initials: A
authors.lastname: Campbell
authors.forename: Kari
authors.initials: K
authors.lastname: Malwitz
authors.forename: Robert S
authors.initials: RS
authors.lastname: Kirkland
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000150:complications / Q000503:physiopathology / Q000523:psychology*; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D051379:Mice; D011388:Prolactin / Q000502:physiology; D011618:Psychotic Disorders / Q000150:complications* / Q000188:drug therapy; D011981:Receptors, Prolactin / Q000187:drug effects / Q000502:physiology
chemical_list: D014150:Antipsychotic Agents; D011981:Receptors, Prolactin; D011388:Prolactin